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Protease-activated receptor 2 (PAR2) is a G protein-coupled
receptor irreversibly activated by extracellular proteases. Acti-
vated PAR2 couples to multiple heterotrimeric G-protein sub-
types including Gq, Gi, and G12/13. Most activated G pro-
tein-coupled receptors are rapidly desensitized and internalized
following phosphorylation and -arrestin binding. However,
the role of phosphorylation in regulation of PAR2 signaling and
trafficking is not known. To investigate the function of phos-
phorylation, we generated a PAR2 mutant in which all serines
and threonines in the C-tail were converted to alanines and des-
ignated it PAR2 0P. In mammalian cells, the addition of agonist
induced a rapid and robust increase in phosphorylation of wild-
typePAR2butnot the 0Pmutant, suggesting that themajor sites
of phosphorylation occur within the C-tail domain. Moreover,
desensitization of PAR2 0P signaling was markedly impaired
compared with the wild-type receptor. Wild-type phosphoryla-
ted PAR2 internalized through a canonical dynamin, clathrin-
and-arrestin-dependent pathway. Strikingly, PAR20Pmutant
internalization proceeded through a dynamin-dependent but
clathrin- and -arrestin-independent pathway in both a consti-
tutive and agonist-dependent manner. Collectively, our studies
show that PAR2 phosphorylation is essential for -arrestin
binding and uncoupling from heterotrimeric G-protein signal-
ing and that the presence of serine and threonine residues in the
PAR2 C-tail hinder constitutive internalization through a non-
canonical pathway. Thus, our studies reveal a novel function for
phosphorylation that differentially regulates PAR2 desensitiza-
tion and endocytic trafficking.
Protease-activated receptor 2 (PAR2)3 is a member of the
protease-activated G protein-coupled receptor (GPCR) family
that includes PAR1, PAR3, and PAR4 (1). PAR2 is expressed in
intestinal and airway epithelial cells, fibroblasts, and in a variety
of cell types of the vasculature and functions in inflammatory
processes associated with tissue injury. PAR2 is also expressed
in certain types of metastatic cancers and stimulates tumor cell
migration and invasion (2, 3). Multiple extracellular proteases
cleave and activate PAR2 including trypsin, mast cell tryptase,
and the coagulation protease factor VIIa in complex with tissue
factor and Xa and others, but not thrombin (4–6). Similar to
other PARs, proteolytic cleavage of PAR2 results in the forma-
tion of a new amino terminus that acts like a tethered ligand by
binding intramolecularly to the receptor to trigger transmem-
brane signaling (4, 7). Synthetic peptides that mimic the teth-
ered ligand sequence of the newly exposed amino terminus can
activate PAR2 independent of proteolytic cleavage. Upon acti-
vation, PAR2 couples to multiple heterotrimeric G-protein
subtypes including Gq, Gi, and G12/13, which signal to a
variety of effectors and promotes diverse cellular responses (1).
Unlike other PARs, however, activated PAR2 also signals inde-
pendently of G-proteins through its interaction with -ar-
restins, which promotes sustained mitogen-activated protein
kinase (MAPK) signaling, actin remodeling, and cell migration
(8–10). The molecular determinants that specify PAR2 cou-
pling to distinct heterotrimericG-protein subtypes and binding
to -arrestins remain to be determined.
The known regulatory processes that control GPCR signal-
ing are based largely on studies of the 2-adrenergic receptor
(11). In the classic paradigm, ligand-activated GPCRs are rap-
idly phosphorylated on serine and threonine residues localized
within the third intracellular loop or cytoplasmic tail (C-tail) by
G protein-coupled receptor kinases (GRKs). -Arrestins are
then rapidly recruited and associate with activated and phos-
phorylated GPCRs at the plasma membrane. The binding of
-arrestins to activated and phosphorylated GPCRs mediates
receptor uncoupling from G-proteins and facilitates receptor
internalization (12–14). Once internalized, some GPCRs signal
from intracellular compartments through stable interaction
with -arrestins, which functions as a scaffold and transducer
ofMAP kinase signaling independent of G-proteins (15). Inter-
nalized GPCRs are then targeted to recycling endosomes,
dephosphorylated, and returned to the cell surface, or sorted to
lysosomes and degraded.
Unlike most classic GPCRs, PAR2 is irreversibly activated by
extracellular proteases. Thus, we hypothesize that PAR2 signal
regulatory mechanisms are likely unique because most other
GPCRs are reversibly activated. We previously reported that
-arrestins are essential for activated PAR2 desensitization and
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internalization. Indeed, in mouse embryonic fibroblasts defi-
cient in -arrestin 1 and 2 expression, PAR2 desensitization
was significantly impaired compared with wild-type -arrestin
expressing cells (16). Internalization of activated PAR2was also
virtually abolished in cells lacking-arrestin 1 and 2 expression
(16). The binding of-arrestins to activatedGPCRs is known to
involve multiple interactions with the receptor intracellular
loops and C-tail (17). Interestingly, activated PAR2 C-tail trun-
cation mutants displayed normal agonist-induced internaliza-
tion, caused rapid redistribution of -arrestins to the plasma
membrane, and desensitized in an -arrestin-dependent man-
ner similar to wild-type PAR2 (16), suggesting that the C-tail of
PAR2 is not critical for rapid -arrestin recruitment. However,
activated PAR2 C-tail mutants lost the capacity to form stable
complexes with -arrestins, and failed to promote sustained
MAP kinase signaling. These findings suggest that the PAR2
C-tail regulates the stability of -arrestin interaction and sus-
tainedMAP kinase signaling, but is not essential for rapid -ar-
restin recruitment nor -arrestin-dependent receptor desensi-
tization or internalization. These findings further suggest that
the diverse functions of -arrestins in the regulation of PAR2
signaling and trafficking are likely to be controlled by distinct
determinants. However, the PAR2-specific determinants that
are critical for the diverse functions of -arrestins in regulation
of receptor signaling and trafficking remain poorly understood.
In the present study, we examine for the first time the role of
phosphorylation in regulation of PAR2 signaling and traffick-
ing. We report that phosphorylation of PAR2 distinctly reg-
ulates desensitization and endocytic trafficking. Our find-
ings further demonstrate that PAR2 phosphorylation is
critical for receptor desensitization and -arrestin binding
and that serine and threonine residues in the PAR2 C-tail
domain impede constitutive internalization and lysosomal
degradation. These studies reveal a novel function for phos-
phorylation in differentially regulating PAR2 desensitization
and endocytic trafficking.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Agonist peptides TFLLRNPNDK
(PAR1-specific) and SLIGKV (PAR2-specific) were synthesized
as the carboxyl amide and purified by reverse-phase high-pres-
sure chromatography (University of North Carolina Peptide
Facility, Chapel Hill, NC). -Trypsin treated with tosylamide-
2-phenylethyl chloromethyl ketone, leupeptin, and cyclohexi-
mide were from Sigma. [32P]Orthophosphate was purchased
from PerkinElmer Life Sciences. Monoclonal M1 and M2 anti-
FLAG, polyclonal anti-FLAG, and anti--actin antibodies were
from Sigma. Anti-early endosome antigen-1 (EEA1) mono-
clonal antibody was purchased from BD Biosciences. Anti-
clathrin monoclonal antibody X22 was from GeneTex, Inc.
(San Antonio, TX). Anti-lysosomal-associated membrane pro-
tein 1 (LAMP1) H4A3 monoclonal antibody was from the
Developmental Studies Hybridoma Bank (University of Iowa,
IowaCity, IA). Anti--arrestin polyclonal antibodyA1CTwas a
gift from R. J. Lefkowitz (Duke University). Horseradish perox-
idase-conjugated goat anti-mouse and goat anti-rabbit second-
ary antibodies were purchased from Bio-Rad (Hercules, CA).
Alexa Fluor 488- and Alexa Fluor 594-conjugated goat anti-
mouse and goat anti-rabbit antibodies were from Invitrogen.
cDNAs and Cell Lines—A cDNA encoding the wild-type
PAR2 containing an amino-terminal FLAG epitope was previ-
ously described (16). PAR2 mutants were generated by site-
directed mutagenesis using QuikChange (Stratagene, La Jolla,
CA), and mutations were confirmed by dideoxy sequencing.
The PAR1 chimera containing the substance P receptor C-tail
(P/S) was previously described (18). The green fluorescent pro-
tein (GFP)-tagged-arrestin 1 and 2 constructs were a gift from
M. Caron (Duke University). The GFP-tagged dynamin K44A
mutant was a gift from M. McNiven (Mayo Clinic and
Foundation).
HeLa cells and Rat1 fibroblasts were cultured as previously
described (16, 18, 19). HeLa cells and Rat1 fibroblasts stably
transfected with FLAG-tagged PAR2 wild-type and mutants
were generated as previously published (18, 19).
siRNAs—HeLa cells were transiently transfected for 72 h
with 100 nM nonspecific siRNA or smart pool siRNAs targeting
the clathrin heavy chain or -arrestin 1 and 2 using Lipo-
fectamine 2000 or DharmaFECT 2 according to the manufac-
turer’s protocol. All siRNAs were purchased from Dharmacon,
Inc. (Lafayette, CO).
Phosphoinositide Hydrolysis—Cells stably expressing
FLAG-tagged PAR2 wild-type or mutants were plated at
0.8  105 cells per well in 24-well plates and grown overnight.
Cells were labeled with 1 Ci/ml of myo-[3H]inositol (Ameri-
can Radiolabeled Chemicals, St. Louis, MO) in serum- and ino-
sitol-free DMEM containing 1 mg/ml of BSA overnight.
[3H]Inositol phosphates (IPs) were measured as previously
described (20).
Receptor Immunoprecipitation, Phosphorylation, and Immu-
noblot Analysis—Rat1 fibroblasts stably expressing FLAG-
tagged PAR2wild-type ormutantswere plated at 3.5 105 cells
per well in 6-well plates and grown for 48 h. Cells were labeled
with 200Ci of [32P]orthophosphate in phosphate-freeDMEM
containing 1 mg/ml BSA for 3 h, washed, and incubated in the
absence or presence of 100 M SLIGKV diluted in DMEM con-
taining 1 mg/ml of BSA and 10 mM HEPES for various times at
37 °C.Cellswere lysedwithTriton lysis buffer (50mMTris-HCl,
pH 7.4, 100 mM NaCl, 5 mM EDTA, 50 mM sodium fluoride, 10
mM sodium pyrophosphate, 200 mM sodium orthovanadate,
and 1% Triton-X-100) containing protease inhibitors. Cell
lysates were immunoprecipitated with M2 anti-FLAG anti-
body, resolved by SDS-PAGE, and transferred to membranes.
Phosphorylated receptor was detected by autoradiography.
The amount of PAR2 in immunoprecipitates was determined
by immunoblotting with polyclonal anti-FLAG antibody and
horseradish peroxidase-conjugated goat anti-rabbit antibody.
HeLa cells stably transfected with FLAG-tagged PAR2 wild-
type or mutants were plated at 1.5  106 cells/well in a 6-well
plate and grown for 48 h at 37 °C. Cells were incubated for
various times with or without 100 M SLIGKV diluted in
DMEM containing 10 M cycloheximide, 1 mg/ml BSA, and 10
mM HEPES. Cells were lysed, immunoprecipitated, and immu-
noblotted as described above. Immunoblots were quantified
using Image J software.
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Cell Surface ELISA—Cells expressing FLAG-tagged PAR2
wild-type ormutantswere plated on fibronectin-coated 24-well
plates and grown for 48 h. After incubations, cells were washed
and fixed with 4% paraformaldehyde. The amount of cell sur-
face receptor was quantitated by incubation with M1 anti-
FLAG antibody at 25 °C for 1 h and horseradish peroxidase-
conjugated goat anti-mouse antibody at 25 °C for 1 h. The
amount of bound secondary antibody was determined by incu-
bating cells with 1-STEP ABTS (2,2-azino-bis-3-ethylbenz-
thiazoline-6-sulfonic acid) (Pierce) for 10–20 min at 25 °C. An
aliquot was taken to measure the optical density at 405 nm
using a Molecular Devices microplate spectrophotometer.
Internalization Assay—Cells stably expressing FLAG-tagged
PAR2 wild-type or mutants were plated on fibronectin-coated
24-well plates and grown for 48 h. Cells were prelabeled with
M1 anti-FLAG antibody for 1 h at 4 °C and then incubated with
or without agonist for various times at 37 °C. The loss of cell
surface receptor was measured by ELISA.
ImmunofluorescenceConfocalMicroscopy—HeLa cells stably
expressing FLAG-tagged PAR2 wild-type or mutant were
plated at 0.8 105 cells/well on fibronectin-coated glass cover-
slips in 12-well plates for 48 h at 37 °C. Cells were washed with
ice-cold DMEM and prelabeled with polyclonal anti-FLAG
antibody on ice for 1 h. Cells were incubated in the absence or
presence of 100 M SLIGKV for 30 min at 37 °C, washed, and
fixedwith 4%paraformaldehyde. Cells were permeabilizedwith
ice-cold 100% methanol and washed with phosphate-buffered
saline containing 1% nonfat dry milk and 150 mM sodium ace-
tate, pH 7.0. Cells were blocked with 1% nonfat dry milk in
phosphate-buffered saline and incubatedwith Alexa Fluor 488-
conjugated goat anti-rabbit anti-
body. For LAMP1 co-localization
studies, cells were incubated in
DMEM containing 2 mM leupeptin,
a lysosomal protease inhibitor, for
37 °C for 1 h. Cells were then pro-
cessed as described above and
immunostained for endogenous
LAMP1, using a monoclonal anti-
LAMP1 antibody for 1 h and Alexa
Fluor 594-conjugated goat anti-
mouse antibody. Cells were imaged
by confocal microscopy as previ-
ously described (21, 22). For clathrin
heavy chain knockdown experi-
ments, endogenous clathrin was
detected using anti-clathrin mono-





PAR2 wild-type or mutants were
plated on fibronectin-coated 24-
well plates and grown for 48 h at
37 °C. Cells were washed and incu-
bated with calcium-dependent M1
anti-FLAG antibody diluted in
DMEM containing 1 mg/ml of BSA, 1 mM CaCl2, and 10 mM
HEPES for 1 h. Cells were incubated in the absence or presence
of 100 M SLIGKV for 60min at 37 °C. Antibody-bound recep-
tor remaining on the cell surface was stripped by washing with
ice-cold phosphate-buffered saline containing 0.4% EDTA to
chelate calcium. Cells were incubated for various times to allow
recovery of antibody-bound receptor to the cell surface. Recep-
tor recovery was measured by cell surface ELISA.
Data Analysis—Prism 3.0 software (GraphPad) was used to
analyze the data and statistical significance was determined
using InStat 3.0 (GraphPad). Statistical analysiswas determined
using one-way analysis of variance and Dunnett’s Multiple
Comparison Test.
RESULTS
Phosphorylation of Activated PAR2 Occurs within the Cyto-
plasmic Tail—To determine the importance of phosphoryla-
tion in the regulation of PAR2 signaling and trafficking, we
constructed a PAR2 mutant in which all serines (Ser) and
threonines (Thr) in the C-tail region weremutated to alanines
(Ala) (Fig. 1A). The PAR2mutant was designated “PAR2 0P.”
We first directly examined the time course of activated PAR2
phosphorylation. Rat1 fibroblasts stably expressing FLAG-
tagged PAR2 wild-type or 0P mutant labeled with
[32P]orthophosphate were incubated in the absence or pres-
ence of saturating concentrations of the PAR2-specific agonist
peptide SLIGKV for various times at 37 °C. PAR2 was immu-
noprecipitated from cell lysates, and phosphorylation was ana-
lyzed by autoradiography. In the absence of agonist, a minimal
amount of wild-type PAR2 phosphorylation was detected (Fig.
FIGURE 1. Agonist-induced phosphorylation of PAR2 occurs within the C-tail region. A, the PAR2 C-tail
serines and threonines are shown in bold and were mutated to alanine to generate the PAR2 0P mutant. B, Rat1
fibroblasts stably expressing comparable amounts of FLAG-tagged PAR2 wild-type or 0P mutant labeled with
[32P]orthophosphate were stimulated with 100 M SLIGKV for various times at 37 °C. Equivalent amounts of cell
lysates were immunoprecipitated with monoclonal M2 anti-FLAG antibody. Receptor immunoprecipitates
were resolved by SDS-PAGE and analyzed by autoradiography. No phosphorylated proteins were detected in
immunoprecipitates from untransfected (UT) Rat1 fibroblasts. Membranes were then probed with a polyclonal
anti-FLAG antibody to detect total PAR2. The asterisk indicates detection of a nonspecific FLAG-positive band
in the UT lane, which is also detected in all PAR2 wild-type and PAR2 0P lanes. The initial amounts (mean  S.D.;
n  3) of cell surface receptor expression measured by ELISA were 0.164  0.033 and 0.112  0.015 OD units for
PAR2 wild-type (WT) and 0P mutant, respectively. IB, immunoblot.
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1B, lanes 1 and 2). This phosphorylation was not observed in
untransfected cells and likely represents basal PAR2 phos-
phorylation. The addition of agonist induced a rapid and signif-
icant peak in activated PAR2 phosphorylation at 2.5 min, and
phosphorylation of PAR2 remained elevated for 30 min in the
continued presence of agonist (Fig. 1B, lanes 3–5). In contrast,
the PAR2 mutant lacking all serines and threonines in the
C-tail, designated PAR2 0P, showed little to no phosphoryla-
tion over the 30-min time course of agonist stimulation (Fig. 1B,
lanes 6–9). Thus, agonist-induced rapid and sustained PAR2
phosphorylation predominantly within the C-tail domain.
Phosphorylation Mediates PAR2 Desensitization—Agonist-
induced phosphorylation and binding of -arrestins mediate
desensitization and internalization ofmany reversibly activated
GPCRs (23). We previously showed that -arrestins are essen-
tial for PAR2 desensitization (16); however, the contribution of
phosphorylation to the termination of PAR2 signaling is not
known. To test the importance of phosphorylation in PAR2
signal regulation we examined agonist-induced desensitization
by quantitating the rate of IP accumulation. Activated PAR2
elicits phosphoinositide (PI) hydrolysis in multiple cell types
(16, 24), an effect attributed to Gq coupling to phospholipase
C-. We initially compared the rates of agonist-induced PI hy-
drolysis in Rat1 fibroblasts and
HeLa cells stably expressing compa-
rable amounts of PAR2 wild-type
and phosphorylation-deficient 0P
mutant on the cell surface. Cells
were incubated with or without a
saturating concentration of trypsin
for various times at 37 °C, and total
[3H]IPs were measured. After 60
min of agonist exposure, a marked
10-fold increase in PI hydrolysis
was detected in wild-type PAR2
expressing Rat1 fibroblasts, whereas
a substantially greater 40-fold
increase in signaling was measured
in cells expressing the phosphoryla-
tion-deficient PAR2 0Pmutant (Fig.
2A). Similarly, in HeLa cells, activa-
tion of phosphorylation-defective
PAR2 0P mutant resulted in a 10-
fold increase in PI hydrolysis, a
response considerably more robust
than that observed in cells express-
ing comparable amounts of wild-
type PAR2 (Fig. 2B). In both PAR2
wild-type and 0Pmutant expressing
HeLa cells, stimulation of endoge-
nous muscarinic acetylcholine
receptors with carbachol resulted in
comparable changes in PI hydroly-
sis, indicating that there are no cell
clone-specific defects in G-protein
signaling (data not shown). These
data suggest that agonist-induced
PAR2 phosphorylation is critical for
termination of G protein signaling.
Next, we examined whether the initial coupling of activated
PAR2 wild-type and 0Pmutant to Gq-promoted PI hydrolysis
was affected. The concentration effect curves for trypsin at the
PAR2 wild-type and phosphorylation-defective 0P mutant
were determined by incubating cells labeled with myo-[3H]-
inositol and varying the concentrations of trypsin for 10 min at
37 °C, and accumulation of [3H]IPswasmeasured. The effective
concentration of trypsin needed to stimulate a half-maximal
response after 10 min was similar for both PAR2 wild-type and
0Pmutant expressed in HeLa cells and significantly different in
Rat1 fibroblasts (p  0.05) (Fig. 2, C and D). Moreover, activa-
tion of the phosphorylation-defective PAR2 0P mutant caused
an enhanced maximal signaling response compared with wild-
type receptor (Fig. 2C) in Rat1 fibroblasts and HeLa cells (data
not shown). These findings suggest that each activatedPAR20P
mutant coupled longer to PI hydrolysis before signaling was
shut off, indicating a slower rate of desensitization.
To determine whether specific phosphorylation sites are
important for regulation of PAR2 signaling a series of receptor
mutants were constructed in which clusters of serines and
threonines within the C-tail were replaced with alanines (Fig.
3A). PAR2 Ser/Thr cluster mutants were stably expressed in
FIGURE 2. Activated PAR2 phosphorylation is critical for desensitization. A, Rat1 fibroblasts, and B, HeLa
cells stably expressing PAR2 wild-type (WT) and 0P mutant labeled with myo-[3H]inositol were incubated in the
absence or presence of 10 nM trypsin for various times at 37 °C, and total [3H]IPs were measured. The data
(mean  S.E.; n  3) shown are expressed as fold-increase over basal [3H]IPs and averaged over three indepen-
dent experiments. C, the concentration effect curves of trypsin at PAR2 wild-type and the 0P mutant were
determined in Rat1 fibroblasts. Cells labeled with myo-[3H]inositol were incubated with varying concentrations
of trypsin for 10 min at 37 °C, and [3H]IPs were measured. The data (mean  S.E.; n  3) shown are averaged
from three independent experiments. D, the effective concentrations of trypsin at PAR2 wild-type and the 0P
mutant determined in Rat1 fibroblasts in C and in HeLa cells using the same experimental conditions. The data
(mean EC50  S.E.; n  3) are averaged from three separate experiments. The initial cell surface receptor
expressions (mean  S.D.; n  3) measured by ELISA in HeLa cells were 0.253  0.022 and 0.196  0.023 OD
units for PAR2 wild-type and the PAR2 0P mutant, respectively.
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Rat1 fibroblasts, and agonist-promoted phosphorylation was
determined. Wild-type PAR2 showed robust phosphorylation
after 2.5 min of agonist activation, whereas phosphorylation of
the PAR2 0P mutant lacking all C-tail serines and threonines
was virtually abolished (Fig. 3B, lanes 1–4). Remarkably, acti-
vation of PAR2 Ser/Thr cluster mutants with SLIGKV for 2.5
FIGURE 3. Activated PAR2 exhibits multiple and/or redundant sites of phosphorylation. A, several PAR2 C-tail serine and threonine cluster mutants were
generated by replacing specific Ser/Thr with alanines as depicted. Cluster mutants were designated as PAR2 S363/6A as previously described (16, 26) and C1–C5
for the remaining cluster mutants. B, Rat1 fibroblasts stably expressing FLAG-tagged PAR2 WT, 0P, or Ser/Thr cluster mutants labeled with [32P]orthophosphate
were incubated in the absence or presence of 100 M SLIGKV for 2.5 min at 37 °C. Cell lysates were immunoprecipitated with M2 monoclonal anti-FLAG
antibody, resolved by SDS-PAGE, and analyzed by autoradiography. The membranes were stripped and reprobed with polyclonal anti-FLAG antibody to detect
total PAR2. C, Rat1 fibroblasts expressing FLAG-tagged PAR2 wild-type, 0P, or Ser/Thr cluster mutants labeled with myo-[3H]inositol were incubated in the
absence or presence of 10 nM trypsin for 60 min at 37 °C, and total [3H]IPs were measured. The data (mean  S.E.; n  3) are expressed as fold-increase over basal
[3H]IPs and averaged from three independent experiments. A significant difference between PAR2 WT and PAR2 0P stimulated PI hydrolysis was detected (*,
p  0.05). The following are initial cell surface receptor amounts measured by ELISA (mean  S.D.; n  3): WT, 0.194  0.027 OD units; 0P mutant, 0.138  0.004
OD units; C1, 0.097  0.013 OD units; C2, 0.136  0.010 OD units; C3, 0.136  0.010 OD units; C4, 0.08  0.015 OD units; C5, 0.182  0.004 OD units.
Phosphorylation-independent Internalization of PAR2
34448 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 49 • DECEMBER 4, 2009
min induced phosphorylation similar to that observed with
wild-type PAR2 (Fig. 3B), suggesting that PAR2 phosphoryla-
tion occurs at multiple and/or redundant sites within the C-tail
domain. To determine whether critical C-tail serine and threo-
nine residues are important for desensitization, we examined
agonist-stimulated PI hydrolysis in cells expressing PAR2 Ser/
Thr cluster mutants (Fig. 3C). Rat1 fibroblasts expressing sim-
ilar amounts of cell surface PAR2 wild-type, 0P, or Ser/Thr
cluster mutants were incubated in the absence or presence of a
saturating concentration of trypsin for 30 min at 37 °C, and
total [3H]IPsweremeasured. All PAR2 Ser/Thr clustermutants
exhibited an increase in agonist-induced PI hydrolysis compa-
rable with wild-type PAR2, whereas the phosphorylation-de-
fective PAR2 0P mutant showed significantly enhanced signal-
ing following agonist incubation. Taken together, these data
suggest that multiple and/or redundant C-tail serine and thre-
onine residues serve as critical sites for agonist-induced PAR2
phosphorylation and desensitization.
PAR2 0P Mutant Internalizes Constitutively—To determine
the role of phosphorylation in PAR2 intracellular trafficking,
we first examined constitutive and agonist-induced receptor
internalization. Rat1 fibroblasts stably expressing FLAG-
tagged PAR2 wild-type or the phosphorylation-deficient 0P
mutant were incubated with M1 anti-FLAG antibody at 4 °C.
Under these conditions only receptors residing on the cell sur-
face binds antibody. Cells were then incubated in the absence or
presence of a saturating concentration of SLIGKV for various
times at 37 °C, and the amount of receptor remaining on the cell
surface was quantified by ELISA. In wild-type PAR2 expressing
cells, agonist induced a rapid receptor internalization within 15
min, leading to a70% loss of cell surface receptor after 60min
(Fig. 4A). The rate of agonist-induced internalization of the
phosphorylation-deficient PAR2 0P mutant was comparable
with the wild-type receptor (Fig. 4A). We next examined con-
stitutive internalization of wild-type PAR2 and observed a slow
rate of internalization resulting in an 5–10% loss of cell sur-
face receptor after 60 min (Fig. 4B). In striking contrast, phos-
phorylation-deficient PAR2 0P mutant displayed an increased
rate of constitutive internalization in which 65% of receptor
was lost from the cell surface after 60 min (Fig. 4B). Similar
findings were also observed in HeLa cells (data not shown).
Immunofluorescencemicroscopy studies ofHeLa cells are con-
sistent with enhanced constitutive internalization of the phos-
phorylation-deficient PAR2 0Pmutant (Fig. 4C). HeLa cells sta-
bly expressing FLAG-tagged PAR2 wild-type or 0P mutant
were incubated in the absence or presence of agonist for 30min
at 37 °C, fixed, immunostained, and analyzed by confocal
microscopy. A substantial amount of internalized phosphory-
lation-deficient PAR2 0P mutant co-localized with EEA1, a
marker of early endosomes in the presence and absence of ago-
nist stimulation or antibody prebinding (Fig. 4C). In contrast,
wild-type PAR2 localized predominantly to the cell surface in
the absence of agonist (Fig. 4C), whereas activated PAR2 wild-
type showed robust internalization and co-localization with
EEA1 (Fig. 4C). To determine whether PAR2 internalization
requires specific serine and threonine residues, we examined
the rates of constitutive and agonist-induced internalization of
PAR2 Ser/Thr cluster mutants (Fig. 4, D and E). Agonist-pro-
moted PAR2 Ser/Thr cluster mutant internalization rates were
comparable with wild-type PAR2 (Fig. 4D). Moreover, consti-
tutive internalization rates of PAR2 wild-type and all Ser/Thr
cluster mutants were similar, whereas the phosphorylation-de-
fective PAR2 0P mutant displayed an enhanced rate of consti-
tutive internalization (Fig. 4E). Collectively, these findings indi-
cate that serines and threonines in the PAR2 C-tail prevent
constitutive internalization and suggest that basal phosphory-
lation and/or a distinct conformation of the PAR2 C-tail regu-
lates cell surface retention.
We next examined whether the phosphorylation-deficient
PAR2 0P mutant internalized through a dynamin-dependent
pathway like wild-type PAR2 (25). HeLa cells expressing PAR2
wild-type or 0P mutant were transiently transfected with GFP-
tagged dynamin K44A mutant, and receptor internalization
was examined by immunofluorescence microscopy. Constitu-
tive internalization of a phosphorylation-deficient PAR2 0P
mutant was substantially inhibited in dynamin K44A mutant
expressing cells, which showed more receptor retained on the
cell surface compared with adjacent cells not expressing
dynaminK44A (Fig. 5A). Indeed, in cells lacking dynaminK44A
expression, the PAR2 0P mutant localized predominantly to
endosomes and not at the cell surface (Fig. 5A, arrowhead).
Internalization of activated PAR2 wild-type and 0P mutant
were also markedly inhibited in dynamin K44A mutant
expressing cells, which displayed more cell surface-localized
PAR2 than adjacent untransfected cells (Fig. 5A, arrowheads).
These findings suggest that internalization of phosphorylation-
deficient PAR2 0P mutant is mediated by dynamin similar to
the wild-type receptor.
To determine the role of clathrin in phosphorylation-defi-
cient PAR2 0Pmutant internalization, we used siRNA targeting
endogenous clathrin heavy chain as previously described (22).
The expression of clathrin heavy chain was substantially
reduced in cells transiently transfected with siRNA specifically
targeting clathrin compared with nonspecific siRNA control as
detected by immunofluorescence microscopy (Fig. 5B, bottom
panels). In cells lacking clathrin expression, activated PAR2
wild-type internalization was considerably impaired with more
receptor retained at the cell surface compared with adjacent
untransfected cells or cells transfected with nonspecific control
siRNA (Fig. 5B). In striking contrast, constitutive and agonist-
induced internalization of phosphorylation-deficient PAR2 0P
mutant occurred regardless of clathrin heavy chain expression
(Fig. 5B). Thus, unlike thewild-type receptor, phosphorylation-
defective PAR2 0P mutant internalization occurs through a
clathrin-independent pathway.
We previously reported that-arrestins are rapidly recruited to
activated PAR2 and are essential for agonist-promoted receptor
internalization (16). To assess the importance of -arrestins in
phosphorylation-deficient PAR2 0P mutant internalization, we
initially examined -arrestin-1-GFP and -arrestin-2-GFP redis-
tribution following the addition of agonist. In untreated PAR2
wild-type expressing cells, -arrestin-1-GFP and -arrestin-2-
GFP remained distributed throughout the cytoplasm, whereas
stimulationwith the agonist peptide SLIGKV for 5min resulted in
-arrestin-GFP rapid redistribution and co-localization with
PAR2 wild-type (Fig. 6, A and B). In contrast, -arrestin-1-GFP
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FIGURE 4. Phosphorylation-deficient PAR2 0P mutant constitutively internalizes. Rat1 fibroblasts stably expressing similar amounts of cell surface PAR2
wild-type (WT) or 0P mutant were incubated with M1 anti-FLAG antibody at 4 °C to label cell surface receptors. Cells were then incubated in medium with (A)
or without (B) 100 M SLIGKV for various times at 37 °C. Cells were fixed, and the amount of antibody-bound receptor remaining on the cell surface was
quantitated by ELISA. The data are shown as the fraction of the initial M1 anti-FLAG antibody-bound receptor at time 0 min. The data (mean  S.E.; n  4) are
averaged from four independent experiments. These cell lines were also used in analyzing PAR2 signaling, and initial cell surface receptor expression was
reported in the legend to Fig. 1. C, HeLa cells expressing PAR2 wild-type or 0P mutant were incubated in the absence or presence of 100 M SLIGKV for 30 min
at 37 °C, fixed, permeabilized, and immunostained for PAR2 (green) using polyclonal anti-FLAG antibody and the early endosomal marker EEA1 (red) using
monoclonal anti-EEA1 antibody. The cells were imaged by confocal microscopy. Co-localization of PAR2 with EEA1 is shown as yellow in the merged image. The
initial cell surface receptor expression in HeLa cells was the same as described in the legend to Fig. 2. Scale bar, 10 m. D and E, Rat1 fibroblasts expressing PAR2
wild-type, PAR2 0P mutant, or PAR2 Ser/Thr cluster mutants were examined for receptor internalization as described above with (D) or without (E) 100 M
SLIGKV for various times. The data (mean  S.E.; n  4) shown are averaged from four separate experiments. Initial cell surface expression was determined by
ELISA and reported in the legend to Fig. 3.
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and -arrestin-2-GFP were not recruited to the cell surface in
phosphorylation-deficient PAR2 0P mutant expressing cells but
remained cytosolic under control, constitutive, and agonist-in-
duced conditions (Fig. 6,C andD).
Previous studies have demonstrated that -arrestins were
essential for wild-type PAR2 internalization (16, 26). To exam-
ine the function of -arrestins in phosphorylation-deficient
PAR2 0Pmutant internalization, we
transfected HeLa cells with siRNAs
targeting endogenous -arrestin 1
and 2. Immunoblot analysis showed
a significant reduction in -arrestin
1 and 2 protein expression in cells
transfected with siRNAs targeting
-arrestins compared with nonspe-
cific siRNA control cells (Fig. 7A).
Similar to previous results in -ar-
restin 1 and 2 null mouse embry-
onic fibroblasts, PAR2 wild-type
failed to internalize in cells
depleted of -arrestins (Fig. 7B)
(16). In contrast, loss of -arrestin
1 and 2 had no effect on constitu-
tive or agonist-induced internal-
ization of the phosphorylation-de-
fective PAR2 0P mutant (Fig. 7B).
These findings suggest that -ar-




PAR2 0P Mutant Constitutively
Sorts to Lysosomes and Degrades
and Does Not Recycle to the Cell
Surface—The increased accumula-
tion of intracellular phosphoryla-
tion-deficient PAR2 0P mutant
observed in the absence of agonist
may result from an increased rate of
constitutive internalization and/or
an inability of the mutant receptor
to recycle or sort to lysosomes for
degradation. We therefore exam-
ined internalization and recycling of
phosphorylation-deficient PAR2 0P
mutant. HeLa cells expressing
FLAG-PAR2 wild-type or 0P mu-
tant were incubated with cal-
cium-dependent M1 anti-FLAG
antibody at 4 °C to label cell surface
receptors and then stimulated with
or without agonist for 60 min at
37 °C. In the absence of agonist,
PAR2 wild-type showed a modest
loss of cell surface receptor after 60
min of incubation at 37 °C (t1),
whereas agonist addition resulted in
an 70% decrease in the level of
PAR2-bound antibody on the cell surface (Fig. 8A). In contrast,
phosphorylation-deficient PAR2 0P mutant expressing cells
not exposed to agonist during the 60-min incubation showed
70% internalization (t1) (Fig. 8B), consistent with enhanced
constitutive internalization. Exposure to agonist peptide
SLIGKV during the 60-min incubation caused a similar 70–
80% decrease in cell surface PAR2 0P mutant (Fig. 8B).
FIGURE 5. Constitutive internalization of PAR2 0P mutant requires dynamin but not clathrin. HeLa cells
were transiently transfected with FLAG-tagged PAR2 wild-type or 0P mutant and GFP-tagged dynamin K44A
(see Fig. 2 for initial cell surface receptor expression). A, cells were labeled with M1 monoclonal anti-FLAG
antibody for 1 h at 4 °C and stimulated with or without 100 M SLIGKV for 30 min at 37 °C. Cells were fixed,
processed, and imaged by confocal microscopy. In GFP-tagged dynamin K44A expressing cells, PAR2 wild-type
and 0P endocytosis was inhibited, whereas in cells lacking dynamin K44A, receptor internalization was partially
impaired (arrowheads). B, HeLa cells stably expressing FLAG-tagged PAR2 wild-type (WT) or 0P were transiently
transfected with clathrin heavy chain (CHC) or nonspecific (ns) siRNA for 72 h. Cells were labeled with M1
monoclonal anti-FLAG antibody for 1 h at 4 °C and then stimulated with or without 100 M SLIGKV for 30 min
at 37 °C. The images shown are representative of at least three separate experiments. Cells were fixed and
processed for confocal microscopy. Cells depleted of endogenous clathrin were immunostained using anti-
clathrin monoclonal antibody 22. Scale bar, 10 m.
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After initial incubationwith orwithout agonist, antibodywas
stripped from the cell surface and recovery of previously inter-
nalized receptor-bound antibody was measured at various
times. In PAR2wild-type expressing cells, little recovery of anti-
body was observed in cells irrespective of agonist incubation
(Fig. 8A). Similarly, in phosphorylation-deficient PAR2 0P
mutant-expressing cells incubated in the absence or presence
of agonist, there wasminimal recovery of internalized antibody
despite the large cohort of receptor-bound antibody that had
been previously internalized (Fig. 8B). In contrast to PAR2, a
chimeric PAR1 bearing the cytoplasmic tail of the substance P
receptor (P/S C-tail) pretreated with the PAR1-specific agonist
peptide TFLLRNPNDK showed substantial recovery of anti-
body on the cell surface with time (Fig. 8C), consistent with its
internalization and recycling as previously reported (18). These
data are consistent with an enhanced rate of phosphorylation-
deficient PAR2 0P mutant internalization and suggest a novel
function for phosphorylation in negative regulation of PAR2
internalization.
To directly test whether the phosphorylation-deficient PAR2
0P mutant constitutively sorts to lysosomes, we used confocal
microscopy to assess whether receptors sort to a LAMP1-pos-
itive compartment. LAMP1 is a specific marker of late endo-
somes and lysosomes. HeLa cells expressing PAR2 wild-type or
0Pmutant were pretreated with or without leupeptin, a lysoso-
mal protease inhibitor, and incubated in the absence or pres-
ence of the peptide agonist SLIGKV for 2.5 h at 37 °C. In the
absence of agonist, PAR2 wild-type localized predominantly to
the surface of cells treated with or without leupeptin (Fig. 9A).
After prolonged agonist exposure, PAR2 was no longer detect-
able in control cells (Fig. 9A), whereas cells pretreated with
leupeptin showed a significant accumulation of receptor in ves-
icles that co-stained for LAMP1 (Fig. 9A). These findings are
consistent with agonist-induced internalization and lysosomal
degradation of wild-type PAR2. In the absence of leupeptin,
little co-localization of phosphorylation-deficient PAR2 0P
mutant and LAMP1 was observed in agonist-treated or
untreated cells (Fig. 9B), suggesting that internalized PAR2 0P
mutant is sorted to lysosomes and rapidly degraded. In contrast
to wild-type PAR2, however, unactivated PAR2 0P mutant was
found largely in LAMP1-positive vesicles in cells pretreated
with leupeptin (Fig. 9B). Similarly, activated PAR2 0P mutant
also localized predominantly to vesicles that co-localized with
LAMP1 after prolonged agonist exposure in leupeptin-treated
cells (Fig. 9B). These results suggest that the phosphorylation-
deficient PAR2 0P mutant undergoes constitutive internaliza-
tion and sorts from endosomes to lysosomes independent of
phosphorylation.
We next directly compared the rates of PAR2 wild-type and
phosphorylation-deficient 0P mutant degradation. HeLa cells
expressing PAR2 wild-type or 0P mutant were incubated with
or without agonist for various times at 37 °C, and the amount of
receptor protein remaining was determined by immunoblot
analysis. PAR2 wild-type expressing cells not exposed to ago-
nist showed a modest basal turnover when de novo receptor
synthesis was inhibited with cycloheximide (Fig. 10A). The
FIGURE 6. PAR2 0P mutant fails to induce -arrestin-1 or -2-GFP translocation. HeLa cells expressing FLAG-tagged PAR2 wild-type (WT) (A, B) or 0P mutant
(C, D) were transiently transfected with -arrestin 1-GFP (A, C) or -arrestin 2-GFP (B, D). Cells were labeled with M1 monoclonal anti-mouse antibody for 1 h at
4 °C before incubating in the absence or presence of 100 M SLIGKV for 5 min at 37 °C. Cells were fixed and processed for confocal microscopy. Control cells
were prelabeled with M1 monoclonal anti-mouse antibody and immediately fixed and processed for confocal microscopy. Control images show cytosolic
-arrestin-1-GFP and -arrestin-2-GFP before stimulation. Images of cells are representative of three independent experiments. Scale bar, 10 m.
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majority of PAR2 species migrated between 36 and 64 kDa,
whereas higher molecular mass species are probably due to
N-linked glycosylation and/or ubiquitination as previously
reported (27, 28). In cells exposed to the agonist peptide
SLIGKV for 2 h, a significant decrease in the amount of PAR2
wild-type protein was observed and the receptor protein was
virtually abolished after 4 h of agonist exposure (Fig. 10B, lanes
FIGURE 7. Constitutive internalization of PAR2 0P mutant occurs inde-
pendent of -arrestins. A, HeLa cells stably expressing FLAG-tagged PAR2
wild-type (WT) or 0P were transiently transfected with -arrestin 1 and 2 or
nonspecific siRNAs for 72 h. The depletion of -arrestin 1 and 2 expression
was determined by immunoblot analysis using polyclonal anti--arrestin
antibody A1CT. Membranes were stripped and reprobed with an anti-actin
antibody as a control for loading. The initial cell surface receptor expres-
sion in HeLa cells was reported as described in the legend to Fig. 2. B, cells
were labeled with polyclonal anti-FLAG antibody for 1 h at 4 °C. Cells were
then treated with or without 100 M SLIGKV for 30 min at 37 °C and pro-
cessed for confocal microscopy. Confocal microscopy images are represent-
ative of results from three independent experiments. Scale bar, 10 m.
FIGURE 8. Phosphorylation-deficient PAR2 0P mutant constitutively
internalizes and does not recycle. HeLa cells stably expressing FLAG-
tagged PAR2 wild-type (WT) (A), 0P mutant (B), or the P/S chimera (C) were
labeled with M1 monoclonal anti-FLAG antibody for 1 h at 4 °C (see Fig. 2
legend for initial cell surface receptor expression). At t0, cells were washed to
remove unbound antibody and stimulated with or without 100 M SLIGKV
(PAR2-specific) or 100 M TFLLRNPNDK (PAR1-specific) for 60 min at 37 °C.
After the initial incubation, cells were washed with phosphate-buffered
saline/EDTA to strip away any antibody-bound receptor remaining on the cell
surface and were then warmed for various times at 37 °C to allow previously
internalized receptor to recover to the cell surface. Cells were then fixed and
recovery of antibody-bound receptor was quantitated by ELISA. The data
(mean  S.D.; n  3) are represented as a fraction of total M1 antibody bound
at time t0, and are from one experiment representative of three independent
experiments.
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2–5). Interestingly, unlike wild-type receptor, unactivated
phosphorylation-deficient PAR2 0P mutant protein was mark-
edly decreased in the presence of cycloheximide and was com-
parable with that observed in agonist-treated cells (Fig. 10, A
andB). These findings are consistentwith constitutive internal-
ization and lysosomal degradation of phosphorylation-defi-
cient PAR2 0P mutant.
DISCUSSION
In the present study, we demonstrate that PAR2 signaling
and endocytic trafficking are differentially regulated by phos-
phorylation. The PAR2 C-tail contains multiple serine and
threonine residues that could serve as potential phosphoryla-
tion sites for GRKs or second messenger protein kinases. Pre-
vious studies showed that pharmacological inhibitors of pro-
tein kinase C enhance PAR2-mediated calcium responses in
KNRK and hBRIE 380 cells, suggesting a role for protein kinase
C in PAR2 desensitization (24). However, whether PAR2 is
directly modified by phosphorylation and the function of such
phosphorylation in regulation of PAR2 signaling and trafficking
remains to be determined.We report here that activated PAR2
phosphorylation is critical for receptor desensitization and
-arrestin recruitment. We found that PAR2 internalization
can proceed independent of G-protein activation and phos-
phorylation. These studies suggest
that phosphorylation and/or a dis-
tinct conformation of PAR2 is
essential for retaining the receptor
at the cell surface. We further show
that the phosphorylation-deficient
PAR2 0P mutant internalizes con-
stitutively and sorts to lysosomes
through a dynamin-dependent but
clathrin- and -arrestin-independ-
ent pathway. Together these studies
suggest that PAR2 internalization
can be uncoupled from G-protein
activation and phosphorylation,
indicating that distinct determi-
nants control the capacity of PAR2
to signal versus recruitment of -ar-
restin and endocytosis.
The mechanisms controlling
GPCR desensitization are best char-
acterized for the photoreceptor rho-
dopsin and 2-adrenergic receptor
(11). In this classic model, ligand-
activated receptors are rapidly
phosphorylated at multiple intra-
cellular serine and threonine resi-
dues by GRKs. Phosphorylation
enhances binding of -arrestins,
which sterically hinders receptor
interactions with G-proteins. Thus,
phosphorylation and -arrestin
binding function together to uncou-
ple the receptor from G-protein
activation and thus, promote signal
termination. We observed a similar mechanism of desensitiza-
tion for PAR2 in which the phosphorylation-deficient PAR2 0P
mutant exhibited a slowed rate of desensitization, suggesting a
defect in uncoupling from G-protein signaling. Moreover, we
previously showed that PAR2 desensitization is severely
impaired in -arrestin 1 and 2 null mouse embryonic fibro-
blasts, indicating that phosphorylation and -arrestin binding
are critical for definitively shutting-off PAR2 signaling (16).
Most activated and phosphorylated GPCRs bind to -ar-
restins, which facilitates receptor recruitment to clathrin-
coated pits and endocytosis. We previously showed that inter-
nalization of wild-type PAR2 is critically dependent on
-arrestins (16), like most classic GPCRs. In the present study,
we found that the phosphorylation-deficient PAR2 0P mutant
was capable of internalization independent of -arrestins.
Interestingly, in the absence of agonist, the PAR2 0P mutant
displayed enhanced endocytosis, whereas unactivated PAR2
wild-type and Ser/Thr clustermutants remained at the cell sur-
face. In addition, constitutive and agonist-induced phosphory-
lation-defective PAR2 0Pmutant internalization occurred nor-
mally in -arrestin 1 and 2 siRNA-depleted cells. In contrast,
siRNA-targeted depletion of -arrestins virtually ablated ago-
nist-induced wild-type PAR2 internalization, consistent with
our previous findings in which wild-type PAR2 internalization
FIGURE 9. Co-localization of PAR2 wild-type and 0P mutant with LAMP1. HeLa cells stably expressing
FLAG-tagged PAR2 wild-type (WT) or 0P mutant were pre-treated with or without 2 mM leupeptin for 1 h at
37 °C. Cells were incubated with polyclonal anti-FLAG antibody for 1 h at 4 °C to label cell surface receptors and
then incubated in the absence (A) or presence (B) of 100 M SLIGKV for 2.5 h at 37 °C. Cells were fixed, pro-
cessed, and immunostained for PAR2 (green) and LAMP1 (red) and imaged by confocal microscopy. Co-local-
ization of PAR2 with LAMP1 is shown as yellow in the merged imaged, and the cells shown are representative
of many cells visualized in three independent experiments. Scale bar, 10 m.
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was completely abolished in -arrestin 1 and 2 null mouse
embryonic fibroblasts (16). Collectively, these findings suggest
that phosphorylation of PAR2 is critical for specifying -arres-
tin recruitment but is dispensable for receptor internalization.
Thus, phosphorylation-deficient PAR2 0P has the capacity to
engage the endocytic machinery and internalizes independent
of -arrestins even in the absence of agonist.
Similar to PAR2, previous studies have shown that phosphor-
ylation is not required for agonist-induced internalization of
CXCR4 or the -opioid receptor (29, 30). -Arrestins are also
dispensable for internalization of muscarinic acetylcholine
receptors, PAR1, and the formyl peptide receptor (20, 31, 32).
Studies of them2muscarinic acetylcholine receptor identified a
Ser/Thr clustermutant that displayed impaired desensitization
of adenylyl cyclase signaling and binding to-arrestins (33, 34),
similar to the phosphorylation-deficient PAR2 0P mutant. In
addition, this m2 muscarinic acetylcholine receptor Ser/Thr
cluster mutant internalized like wild-type receptor in human
embryonic kidney 293 cells, and overexpression of -arrestin 1
or -arrestin 2 had no effect on its internalization. The authors
concluded that m2muscarinic acetylcholine receptor predom-
inantly uses an -arrestin-independent pathway for receptor
internalization and that phosphorylation may regulate both
-arrestin-dependent and -arrestin-independent activities
(33). In the case of PAR1, unactivated receptor internalizes con-
stitutively through clathrin-coated pits independent of phos-
phorylation and -arrestin binding. Rather than -arrestins,
PAR1 constitutive endocytosis is mediated by adaptor protein
complex-2, in which the 2-subunit binds directly to a distal
tyrosine-based motif within the receptor C-tail (35). The adap-
tor protein that mediates constitutive internalization of the
phosphorylation-deficient PAR2 0P mutant is not known.
Finally, we cannot exclude the possibility that mutating the
PAR2 C-tail disrupts a conformation of the receptor important
for cell surface retention and/or receptor endocytosis. Thus,
our results suggest that phosphorylation and/or a distinct con-
formation of the C-tail domain of PAR2 are critical for nega-
tively regulating receptor internalization and specifying endo-
cytosis through an -arrestin-dependent pathway.
PAR2 appears to internalize through a dynamin-dependent
but clathrin- and -arrestin-independent pathway in the
absence of phosphorylation. Most classic GPCRs bind -ar-
restins, which engages adaptor protein complex-2 and the
clathrin heavy chain to promote receptor internalization
through a dynamin- and clathrin-dependent pathway; how-
ever, some GPCRs utilize a dynamin-dependent but clathrin-
independent mode of endocytosis (36). Clathrin-independent
endocytosis can occur through lipid rafts, membrane microdo-
FIGURE 10. Phosphorylation-deficient PAR2 0P mutant is constitutively sorted to lysosomes and degraded. HeLa cells expressing FLAG-tagged PAR2
wild-type (WT) (A) or 0P mutant (B) were incubated with or without 100 M SLIGKV for various times at 37 °C in the presence of 10 M cycloheximide to prevent
new receptor synthesis. Equivalent amounts of cell lysates were immunoprecipitated with M2 anti-FLAG antibody, and the amount of PAR2 remaining was
detected by immunoblot analysis. Untransfected (UT) HeLa cells are shown in the adjacent lanes. The asterisk indicates detection of a nonspecific FLAG-positive
band in the UT lane, which is also detected in all PAR2 wild-type and PAR2 0P lanes. Immunoblot data (mean  S.E.; n  2) was quantified using Image J software
and plotted as a fraction of untreated control cells.
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mains that are highly enriched in cholesterol and glycosphin-
golipids (37). A distinct subset of lipid rafts known as caveolae
form flask-shaped pits at the plasma membrane and are
enriched in the structural scaffolding protein caveolin. Caveo-
lin is thought to sequester membrane proteins, including
GPCRs, into caveolae through protein-protein interactions
with caveolin binding motifs. We have identified a putative
caveolin-bindingmotif within the carboxyl-terminal portion of
the seventh transmembrane domain of PAR2 (YXFVSHDF,
XXXXX), whichmay confer an interactionwith caveolin to
facilitatemovement into caveolarmembranes and endocytosis.
Indeed, in MDA-MB-231 cells, a fraction of PAR2 is present in
caveolin-1 positive and detergent-resistant lipid fractions and
co-localizes with caveolin-1 as assessed by immunofluores-
cencemicroscopy (38).However,whether PAR2 and caveolin-1
directly interact has not been determined. The phosphoryla-
tion-deficient PAR2 0P mutant may also utilize other clathrin-
independent modes of endocytosis via non-caveolar pathways.
In lymphocytes deficient in caveolin-1, the interleukin-2 recep-
tor partitioned into detergent-resistant fractions and internal-
ized through a clathrin-independent but dynamin- and RhoA-
dependent pathway (39). It is unclear, however, whether RhoA
activity mediates PAR2 redistribution into lipid rafts and/or
facilitates receptor endocytosis.
Our studies further suggest that internalized PAR2 can sort
from endosomes to lysosomes in the absence of receptor acti-
vation and phosphorylation. The 2-adrenergic receptor and
CXCR4 traffic from endosomes to lysosomes through a
ubiquitin-dependent pathway (40, 41). Ubiquitinated cargo
interacts with the ubiquitin bindingmotif of hepatocyte growth
factor-regulated tyrosine kinase substrate (HRS) (42). HRS
associates with early endosomalmembranes and sorts ubiquiti-
nated proteins from early endosomes to late endosomes. HRS
also directly binds to tumor suppressor gene product 101
(Tsg101) of the ESCRT complex, which is required formultive-
sicular body formation, lysosomal fusion, and subsequent deg-
radation of proteins and lipids. A recent study showed that
activated PAR2 is ubiquitinated by the E3 ligase Cbl, and a
receptor mutant that is not ubiquitinated fails to degrade in the
presence of agonist (27). In addition, post-endocytic sorting of
PAR2 requires HRS, but the role of Tsg101 and other members
of the ESCRTmachinery is currently unknown (43). In contrast
towild-type PAR2, the -opioid receptor andPAR1 sort to lyso-
somes independent of ubiquitination (44, 45). Interestingly,
-opioid receptor still requires HRS for lysosomal sorting, sug-
gesting alternative sorting mechanisms of HRS for non-ubiq-
uitinated cargo (46). PAR1 sorts to lysosomes independent of
HRS and Tsg101 but requires SNX1, a protein that functions in
vesicular trafficking (21). Whether phosphorylation-deficient
PAR2 0P mutant is ubiquitinated and sorts to lysosomes
through an ESCRT-dependent or -independent pathway re-
mains to be determined.
Together our studies reveal a novel function for phosphory-
lation that differentially regulates PAR2 signaling and traffick-
ing. However, whether GRKs or second messenger kinases
phosphorylate PAR2 at distinct sites to differentially regulate
PAR2 signaling and trafficking is not known and an important
future pursuit. Moreover, the role of PAR2 phosphorylation in
possibly regulating distinct functions of -arrestins warrants
further investigation. The binding of -arrestins to activated
and phosphorylated GPCRs appears to be independent of a
consensus sequence or phosphorylation-specific sites; how-
ever, recent studies suggest that phosphorylation by specific
GRKs can have differential effects on -arrestin function (47).
The depletion ofGRK2 by siRNAknockdown reducedV2 vaso-
pressin and AT1A angiotensin receptor phosphorylation and
inhibited receptor internalization and desensitization, whereas
loss of GRK 5/6 only prevented prolonged MAPK activation
(48, 49). Thus, it is possible that -arrestins form a different
active conformation when bound to GRK2- versus GRK5/6-
phosphorylation sites and in turn, confer different -arrestin-
mediated functions (47). Thus far, we have been unable to iden-
tify specific phosphorylation sites in PAR2 that might
differentially regulate-arrestin function, suggesting that other
determinants may also contribute to the diverse regulatory
mechanisms that control PAR2 signaling and trafficking.
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